Cervomed Inc CRVO

$3.02 +0.09 (3.07%)

Valuation

Market cap
44,299,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
PE ratio
0.00
Forward PE
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
224,400
Avg volume
263,294
Day's range
$2.88 – $3.07
Shares out
15,119,000
Stochastic %K
92%
Beta
-0.75
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

generaltom Oct 2, 8:49 PM
$CRVO ok volume again today. Will the price keep rising as the anticipation of read outs plus partnership potential get closer. That’s the question. I think so.
0 replies
BPler Oct 2, 7:40 PM
$CRVO
0 replies
Houseofsweeps Oct 2, 7:37 PM
$CRVO
0 replies
5layer Oct 2, 3:05 PM
$CRVO .
0 replies
Will05UW Oct 2, 1:13 PM
$CRVO John Alam and Joshua Boger possess a significant advantage in soliciting a partnership: they do not need to rely on cold outreach. The drug they are developing, neflamapimod, was originally discovered at Vertex Pharmaceuticals during Boger’s tenure as CEO. Because of this, the asset's history and their leadership are already well-known within elite biopharma circles. Socializing this opportunity among their extensive network of industry leaders is not only possible—it is the core channel through which they should initiate a deal. To execute this outreach effectively, they should deploy a two-pronged strategy combining targeted executive socialization with a structured corporate development process.
1 replies
ibaian Oct 2, 12:56 PM
$CRVO The global Lewy body Dementia treatment market is projected to reach $8.45 billion by 2033.
0 replies
generaltom Oct 2, 4:58 AM
$CRVO corporate presentation was updated a few days ago. They have removed the overall target of 5 billion peak sales opportunity and now just focus on the regional opportunities specifically. I think this reflects the regional licensing and partnership model they are now working on. Presentation also confirms partnership is targeted for H2 26, so within the next few months.
0 replies
Max_Prophet26 Oct 2, 1:25 AM
$BENF Current watchlist: $BIRD $BENF $CRVO $LVWR $XPOF
0 replies